HC Wainwright started coverage on shares of SOPHiA GENETICS (NASDAQ:SOPH – Free Report) in a report issued on Monday, MarketBeat.com reports. The brokerage issued a buy rating and a $12.00 target price on the stock. HC Wainwright also issued estimates for SOPHiA GENETICS’s Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.58) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.01) EPS, FY2027 earnings at ($0.20) EPS, FY2028 earnings at $0.04 EPS, FY2029 earnings at $0.34 EPS and FY2030 earnings at $0.69 EPS.
A number of other equities research analysts also recently issued reports on the company. BTIG Research reissued a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $9.00.
Check Out Our Latest Stock Analysis on SOPH
SOPHiA GENETICS Stock Performance
SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The company had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. Analysts expect that SOPHiA GENETICS will post -0.58 EPS for the current year.
Insider Buying and Selling at SOPHiA GENETICS
In other SOPHiA GENETICS news, CEO Ross Muken sold 9,838 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $5.22, for a total value of $51,354.36. Following the transaction, the chief executive officer directly owned 670,651 shares of the company’s stock, valued at $3,500,798.22. This trade represents a 1.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 7,393 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $5.17, for a total value of $38,221.81. Following the transaction, the insider owned 614,887 shares in the company, valued at approximately $3,178,965.79. This represents a 1.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 176,711 shares of company stock worth $959,913. Corporate insiders own 4.88% of the company’s stock.
Institutional Investors Weigh In On SOPHiA GENETICS
Hedge funds have recently modified their holdings of the stock. Silverberg Bernstein Capital Management LLC grew its position in SOPHiA GENETICS by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after acquiring an additional 4,155 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares in the last quarter. First Dallas Securities Inc. purchased a new position in shares of SOPHiA GENETICS in the first quarter valued at $50,000. Finally, Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS in the third quarter valued at $49,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.
Key Stories Impacting SOPHiA GENETICS
Here are the key news stories impacting SOPHiA GENETICS this week:
- Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $12 price target, suggesting meaningful upside from current levels and boosting sentiment around SOPHiA GENETICS’s longer-term growth story.
- Positive Sentiment: The same research note laid out an improving earnings path, with SOPHiA GENETICS expected to narrow losses in 2026-2027 and turn profitable by FY2028, while projecting stronger earnings in FY2029 and FY2030.
- Neutral Sentiment: The company announced it will report second-quarter 2026 results on August 4, which typically increases trading interest as investors position ahead of the earnings release. SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
- Neutral Sentiment: A media appearance featuring the CEO discussing how AI could personalize patient therapies reinforces the company’s AI-driven precision medicine narrative, but it is not a direct financial catalyst. SOPHiA GENETICS CEO says AI will personalize patient therapies
- Negative Sentiment: The analyst estimates still point to continued losses in the near term, including FY2026 EPS of ($0.58) and FY2027 EPS of ($0.20), which may temper enthusiasm despite the bullish target price.
About SOPHiA GENETICS
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Read More
- Five stocks we like better than SOPHiA GENETICS
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
